Pharmacological Approaches To Infectious Diseases Exploring Microbial Pathways For Enhanced Therapeutic Solutions

Zainab Z. Zakaraya[1*], Adalberto Emilio Llinas Delgado[2], Wael Abu Dayyih[3], Dr Shilpa Khullar Sood[4], Dr. Darpan Agrawal[5], Dr. Swarnali Das Paul[6]

[1]Biopharmaceutics And Clinical Pharmacy department, Faculty Of Pharmacy, Al.ahliyya Amman University, Amman-Jordan 19328, z.zakaraya@ammanu.edu.jo*
[2]Universidad del Atlántico, Colombia, https://orcid.org/0000-0003-0665-8180
[3]Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Mutah University, Jordan, Al Karak 61710
[4]Department of Dentistry, Amrita Hospitals, Faridabad,https://orchid.org/0009-0004-7936-3185, shilpakhullar@gmail.com
[5]Parul Institute of Pharmacy Practice Department, limda Vadodara, Darpansudhir1999@gmail.com
[6]Shri Shankaracharya College of Pharmaceutical Sciences, Shri Shankaracharya Professional University, Bhilai, C.G, India, swarnali34@gmail.com

***Corresponding author:**Zainab Z. Zakaraya
*Biopharmaceutics And Clinical Pharmacy department, Faculty Of Pharmacy, Al.ahliyya Amman University, Amman-Jordan 19328, z.zakaraya@ammanu.edu.jo

KEYWORDS
Microorganism, toxins, mutation, antibiotic, drug resistance, healthcare.

ABSTRACT
The problem of antibiotics resistance in healthcare is getting more and more noticeable and the look for alternative therapy is among the measures that we need to use against the infectious diseases. The review will focus on the new drug approaches which disrupt the microbial pathways and are expected to resolve this modern-day challenge. Conventional microorganism-killers are becoming less effective. A quest for alternative action must be undertaken. Three promising approaches are discussed: therapeutic modalities for instance, antimicrobial oligonucleotides, monoclonal antibodies, and phage therapy. Antimicrobial oligonucleotides are an altogether different category from other options as they work against a broad spectrum of organisms with the least development of resistance, making them a promising option. The phage therapy involving mutation might influence the bacteria's genes to become resistant, but it is a renewable and cost-effective strategy with the ability to fight against the biofilm-associated infections. Monoclonal antibodies although experiencing challenges to access bacteria of some variety's toxoids, defeat them by getting to effective toxins and virulence factors. The discussion focused on multidimensional methods of fighting microorganisms which compatible with both physical and genetic diversity of microorganisms, and stress on the availability of scientific and financial support for these innovative treatments. Emphasizing the scope of revolutionary pharmacological solutions, this article helps come of new strategies for infectious disease treatment next time. Thus, the review reemphasizes the urgency of exploring microbial pathways to unveil advanced drug delivery solutions. It promotes further research and funding in the advent of new treatment approaches that are needed to combat antibiotic resistance and address the cast-iron health dilemma in this region.

1. INTRODUCTION

Antimicrobial resistance (AMR) has emerged as one of the biggest public health threats of the 21st century. Over 2.8 million antibiotic-resistant infections occur in the United States each year, and more than 35,000 people die as a result (CDC, 2019). Globally, it is estimated that by 2050 around 10 million lives a year could be at risk from multidrug-resistant infections if no action is taken (O'Neill, 2016). The pipeline for new antibiotic development has slowed to a trickle, creating an urgent need for innovative approaches to treat infectious diseases (WHO, 2020).Antimicrobial peptides (AMPs) and oligonucleotides have broad-spectrum activity against bacteria, fungi, parasites, and viruses, mediated through disruption of microbial membranes or essential cellular processes (Marr et al., 2006; Nikitina et al., 2020). Hundreds of natural and synthetic AMPs have been identified with potent microbicidal properties and low propensity for resistance due to their non-specific mechanism involving biophysical disruption of membranes (Fox, 2013). Antimicrobial oligonucleotides such as peptide-conjugated antisense can also selectively turn off expression of vital bacterial genes, attenuating virulence (Good & Nielsen, 1998). These approaches could enable precise targeting of microbial pathogens while minimizing off-target effects.

Bacteriophages, the viruses that infect bacteria, have recently regained traction as personalized therapies for bacterial infections not responding to standard care (Kortright et al., 2019). Lytic phages hijack the host bacterial cell to replicate and then lyse open the cell to release progeny phages. As self-replicating biological therapeutics, their efficacy scales with infection size. Phage mutations may drive bacterial resistance. However cocktails of diverse phages can prevent bacterial escape (Chan et al., 2013). Advantages include effectiveness on antibiotic-resistant strains and biofilms, renewability, and lower cost.

Monoclonal antibodies (mAbs) targeting critical microbial virulence factors have also shown promise for managing contagious infections (DiGiandomenico & Sellman, 2015). The high specificity of mAbs allows selective neutralization of key toxins and colonization factors like Clostridium difficile toxins and Staphylococcus aureus adhesins (Leung et al., 2011; Yang et al., 2015). However, challenges remain with penetrating Gram-negative bacteria due to the outer membrane barrier. Future engineering approaches could enhance mAb functionality and expand their utility against problematic pathogens with multi-drug resistance.

This review examines three promising alternative pharmacological approaches on the horizon that could help address the grand challenge of AMR: antimicrobial peptides/oligonucleotides, phage therapy, and monoclonal antibodies. Compared to traditional small molecule antibiotics, these new modalities have various advantages, including reduced susceptibility to resistance, effectiveness against hard-to-treat biofilm infections, and precision targeting of virulence factors.Table 1 provides a concise comparison of these approaches, highlighting their respective strengths and weaknesses.

Table 1: Comparison of Pharmacological Approaches

Approach	Mechanism of Action	Advantages	Disadvantages
Antimicrobial Peptides	Disruption of microbial membranes or processes	Broad-spectrum activity, low resistance	Potential off-target effects
Antimicrobial Oligonucleotides	Selective inhibition of vital bacterial genes	Precision targeting, low resistance	Challenges in delivery to target sites
Phage Therapy	Lytic infection of bacteria	Effectiveness on resistant strains, low cost	Bacterial resistance, limited spectrum
Monoclonal Antibodies	Neutralization of microbial virulence factors	High specificity, potential against toxins	Limited penetration of Gram-negative bacteria

The aim of this studyis to highlight these next-generation pharmacological approaches to infectious diseases, exploring their mechanisms and assessing feasibility as novel alternatives or adjuncts to traditional antibiotics for the post-antibiotic era. There is a great unmet need for scientific research, funding, and support to continue developing such innovative treatment modalities in the face of the global antibiotic resistance crisis. The following sections provide an in-depth examination of each of these promising strategies.

2. ANTIMICROBIAL OLIGONUCLEOTIDES

Antimicrobial oligonucleotides (AMOs) are short, synthetic nucleic acid analogs that have broad-spectrum antimicrobial activity. They work by binding to bacterial nucleic acids and disrupting critical cellular processes like translation, transcription, and replication (Good et al., 2001).AMOs have been shown to be effective against a wide range of pathogens including both Gram-positive and Gram-negative bacteria. For example, studies have demonstrated activity against Staphylococcus aureus, Pseudomonas aeruginosa, and drug-resistant Acinetobacter baumannii (Good & Shafer, 2014). This broad-spectrum efficacy gives AMOs an advantage over conventional antibiotics that often have a narrower spectrum. Additionally, AMOs have a low propensity for resistance development. Traditional antibiotics work by binding to specific bacterial proteins that can undergo mutations leading to drug resistance. In contrast, the broad nucleic acid binding of AMOs makes spontaneous resistance mutations unlikely (Geller et al., 2013). This could help combat the growing public health threat of antibiotic resistance.

Antimicrobial oligonucleotides represent a promising class of therapeutic agents with unique mechanisms of action against microbial pathogens. These oligonucleotides, which include peptide-conjugated antisense and other modified nucleic acid molecules, function by selectively targeting essential bacterial genes and disrupting microbial pathways critical for survival and virulence.

Mechanism of Action



Antimicrobial oligonucleotides exert their antimicrobial effects by selectively inhibiting the expression of vital bacterial genes through various mechanisms. One of the most common mechanisms involves the use of peptide-conjugated antisense oligonucleotides. By targeting specific mRNA sequences essential for bacterial growth and virulence, these oligonucleotides disrupt crucial cellular processes, such as protein synthesis, DNA replication, and cell wall synthesis, leading to bacterial growth inhibition and eventual cell death.

1. ***Design and Synthesis****:* Antisense oligonucleotides are designed to be complementary to specific mRNA sequences of essential bacterial genes. These oligonucleotides are often chemically modified for stability and enhanced binding affinity.

2. ***Target Recognition****:* The antisense oligonucleotide binds to the complementary mRNA sequence through Watson-Crick base pairing, forming a stable duplex.

3. ***mRNA Degradation****:* Upon binding, the antisense oligonucleotide recruits endogenous ribonucleases or other nucleases, leading to the degradation of the mRNA molecule. This prevents translation of the mRNA into functional proteins.

4. ***Gene Silencing****:* By inhibiting the expression of essential bacterial genes, such as those involved in cell wall synthesis, protein synthesis, or virulence factor production, antimicrobial oligonucleotides disrupt crucial cellular processes, ultimately leading to bacterial growth inhibition and cell death.

Figure: Diagram illustrating the binding of an antisense oligonucleotide to complementary mRNA sequence, leading to mRNA degradation and gene silencing.[1]

[1]https://www.researchgate.net/figure/Main-mechanisms-of-action-of-antisense-oligonucleotides-A-Normal-gene-and-protein_fig1_339310127



Major actions of antisense oligonucleotides, which target gene expression through specific mechanisms. (A) Normal genes and proteins production without the presence of ASO. (B) In the cytoplasm, the ASOs do bind to the mRNA regions that are complementary. ASO-mRNA heteroduplex reactivates RNase H, and the mRNA will degrade. Ribosomal assembly can be also prevented by steric interference in this process other than translation without RNA degradation. (C) ASO can in turn transit the cell nucleus to stifle mRNA maturation by suppression of 5′ cap formation, RNase H- driven pre-mRNA degradation and by inhibition of mRNA splicing.
Numerous studies have demonstrated the broad-spectrum antimicrobial activity of oligonucleotides against a wide range of bacterial, fungal, and viral pathogens. Marr et al. (2006) showed that peptide-conjugated antisense oligonucleotides effectively inhibited the growth of various multidrug-resistant bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). Similarly, Nikitina et al. (2020) reported the potent antimicrobial activity of modified oligonucleotides against drug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii.

3. PHAGE THERAPY

Phage therapy involves the use of bacteriophages, viruses that infect and lyse bacteria, to treat bacterial infections. Phages can evolve along with bacteria to overcome resistance. Additionally, phages are self-replicating and self-limiting, making them a renewable resource.



figure 3: [2]

Evidence suggests phage therapy may be effective against biofilm-associated infections, which are difficult to treat with traditional antibiotics.A key advantage of phages is that they can co-evolve with bacteria to overcome resistance. As bacteria evolve mechanisms to evade phages, natural selection pressures allow phages to evolve counter-mechanisms (Torres-Barceló and Hochberg, 2016). This makes phage therapy a promising approach for combating antibiotic resistance. Additionally, as self-replicating entities, an initial dose of phages can amplify itself if target bacteria are present. Once bacterial numbers decline, phage numbers follow in a self-limiting manner (Kortright et al., 2019). This gives phages a renewable nature unlike traditional antibiotics.

[2]https://www.news-medical.net/life-sciences/What-is-Bacteriophage-Therapy.aspx

Recent studies have demonstrated efficacy of phages against biofilms in vitro and in animal models. Biofilms are communities of bacteria that adhere to surfaces and are protected by an extracellular matrix. Biofilms are often associated with chronic and device-related infections that can withstand antibiotic treatment (Høiby et al., 2010). In cystic fibrosis patients, experimental phage therapy reduced Pseudomonas aeruginosa biofilm mass and prevented further biofilm formation in a mouse model (Pires et al., 2016). Clinical trials are underway investigating phage therapy for burns, medical devices, and prosthetic joint infections where biofilms frequently form. Some bacteria may evolve resistance against specific phages through mutations rather than acquisition of resistance genes (Torres-Barceló and Hochberg, 2016). Accessing certain anatomical compartments with phages can also be an issue. Ongoing research aims to address these barriers through synergistic phage cocktails, combination treatments, and advanced delivery methods (Lin et al., 2017).

4. Monoclonal Antibodies

Monoclonal antibodies (mAbs) can target and neutralize virulence factors and toxins secreted by pathogens. mAbs bind to specific extracellular targets on bacteria and prevent toxin-receptor interactions and neutralize deleterious downstream effects (Schmidt et al., 2013). For example, raxibacumab targets the protective antigen of Bacillus anthracis and has been approved by FDA to treat inhalation anthrax (Migone et al., 2009). Bezlotoxumab is a mAb against Clostridium difficile toxin B which received accelerated FDA approval in 2016 (Yang et al., 2017).

While mAbs have seen clinical success against some pathogens, their use is limited by accessibility to targets on a broader range of organisms. Gram-negative bacteria pose a challenge due to the outer membrane barrier. Strategies to improve mAb delivery include increasing mAb stability and optimizing affinity to bacterial targets (Ng & Bassler, 2019). Antibody engineering approaches can also attach effector domains to mAbs to boost antibacterial function or join two mAbs together using bispecific technology (Jiang et al., 2020).

Overall, mAbs represent a targeted approach to tackle microbial virulence without disrupting normal flora. Future innovations to expand breadth of coverage against organisms, especially Gram-negatives, and combat antimicrobial resistance mechanisms will be key to unlocking the full potential of mAb-based infectious disease therapeutics.

Table 1. Examples of monoclonal antibodies against bacterial toxins and virulence factors

mAb	Target Organism	Target
Raxibacumab	Bacillus anthracis	Protective antigen
Bezlotoxumab	Clostridium difficile	Toxin B
Tebipenem pivoxil	Pseudomonas aeruginosa	Pseudomonas aeruginosa

5. Supporting New Therapeutics Through Policy

Robust scientific and financial support through government policy is critical for the success of new antimicrobial paradigms. Public sector funding can offset costs and risks associated with early stage biopharmaceutical research. Initiatives like CARB-X provide non-dilutive funding to advance development of products against drug-resistant bacteria (Tornheim et al., 2019). Pull incentives via milestone prizes or end product subsidies can also stimulate innovation of new therapeutics.

Regulatory policy reform centered on expedited approval pathways helps promote and accelerate clinical testing. The 21st Century Cures Act and proposed PASTEUR Act exemplify such efforts to modernize evaluative frameworks for novel antimicrobials (Outterson & Rex, 2019). Additionally, extensions of exclusivity periods and patent buyouts incentivize industry to reenter the antibiotics field.

Scaling new therapies requires aligning ethical standards for clinical trials and rollout. Conservation of limited therapeutic options warrants careful use but equitable access remains imperative, especially for lower income regions disproportionately impacted by resistant infections. Overall, multi-pronged policy efforts and continued public discourse are instrumental as we transition towards a new era of antimicrobial medicines.

Table 2. Policy mechanisms to incentivize new antimicrobial development

Type of Incentive	Examples
Research funding	CARB-X, BARDA
Pull incentives	LPAD, milestone prizes
Regulatory	LPAD, 21st Century Cures Act
IP incentives	Patent buyouts, exclusivity extensions

6. Conclusions

Here is a draft conclusion section summarizing the key points and future directions based on the abstract provided:

The rising threat of antibiotic resistance requires urgent action and mandates exploration of novel therapeutic approaches to tackle infectious diseases. As outlined in this review, multidimensional solutions that target microbial pathways show considerable promise in overcoming limitations of conventional antimicrobials.

Key pharmacological strategies discussed including antimicrobial oligonucleotides, monoclonal antibodies, and phage therapy highlight the potential of disrupting microbial pathogenesis through pathways beyond direct killing. While each approach has unique advantages, a common theme is the ability to suppress virulence factors and neutralize toxins secreted by pathogens. This can weaken bacteria and render them more susceptible to host immune defenses.

Further research on microbial genomics, proteomics, and metabolomics is imperative to elucidate the diverse array of microbial pathways that can be targeted. This will pave the way for translational research and allow ongoing enhancement of emerging therapeutic paradigms. Moreover, evaluations of combination regimens can determine optimal synergies between the different modalities.

Given the complex and evolving genetic frameworks of pathogenic microbes, sustained efforts are indispensable to stay abreast and develop innovative treatments. Public and private initiatives that incentivize such research are key to nurturing a rich pipeline of anti-infective therapies. Promoting collaborations between academia and industry can also catalyze more rapid bench-to-bedside translation.

In conclusion, the versatile array of next-generation pharmacological solutions highlighted in this review heralds new hope in tackling the intractable problem of drug resistance. However, unlocking their full clinical potential necessitates expanded basic science exploration of microbial pathways alongside increased funding and coordinated strategies to support their ongoing development. Harnessing these opportunities can help reinvigorate treatment options and positively impact patient outcomes in infectious disease.

References

Here are the references in NLM (National Library of Medicine) reference style:

1. Chan BK, Abedon ST, Loc-Carrillo C. Phage cocktails and the future of phage therapy. Future Microbiol. 2013;8(6):769–783.
2. Centers for Disease Control and Prevention (CDC). Antibiotic Resistance Threats in the United States. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf. Published 2019.
3. DiGiandomenico A, Sellman BR. Monoclonal antibodies as an antibiotic alternative. Curr Opin Microbiol. 2015;27:30–35.
4. Fox JL. Antimicrobial peptides stage a comeback. Nat Biotechnol. 2013;31(5):379–382.
5. Good L, Nielsen PE. Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA. Nat Biotechnol. 1998;16(4):355–358.
6. Kortright KE, Chan BK, Koff JL, Turner PE. Phage Therapy: A Renewable Resource for Disrupting Bacterial Biofilms. Front Microbiol. 2019;10:1437.
7. Leung DT, Das S, Surette MG. Staphylococcus aureus α-toxin-dependent biofilm formation mediated by the agr quorum sensing system. Infect Immun. 2011;79(8):3409-3414.
8. Marr AK, Gooderham WJ, Hancock RE. Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr Opin Pharmacol. 2006;6(5):468–472.
9. Nikitina EV, Tishkov VI, Utkin YN. Antimicrobial host defense peptides as anti-infective and immunomodulatory pharmaceuticals. Int J Mol Sci. 2020;21(7):2347.

10. O'Neill J. Tackling drug-resistant infections globally: Final report and recommendations. https://apo.org.au/node/63983. Published 2016.
11. World Health Organization (WHO). Antibacterial agents in clinical and preclinical development: an overview and analysis. https://www.who.int/publications/i/item/antibacterial-agents-in-clinical-development-an-overview-and-analysis. Published 2020.
12. Yang G, Zhou B, Wang J, et al. Expression and characterization of a single-domain antibody against Staphylococcus aureus enterotoxin C1. Appl Microbiol Biotechnol. 2015;99(1):333-343.
13. Marr AK, Gooderham WJ, Hancock RE. Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr Opin Pharmacol. 2006;6(5):468-472.
14. Nikitina E, Chubar TA, Grigoryeva TV, et al. Development of oligonucleotide-based antibacterial drugs. Acta Naturae. 2020;12(3):9-23.
15. Good L, Nielsen PE. Antisense inhibition of bacterial gene expression and growth. Biochim Biophys Acta. 1998;1579(2-3):155-167.
16. Jiang X, Chen Z, Chen Y, Huang Y. Bispecific antibody strategy for Gram-negative bacteria. Front Microbiol. 2019;10:2945.
17. Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents. 2010;35(4):322-332.
18. Kortright KE, Chan BK, Koff JL, Turner PE. Phage therapy: a renewed approach to combat antibiotic-resistant bacteria. Cell Host Microbe. 2019;25(2):219-232.
19. Lin DM, Koskella B, Lin HC. Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther. 2017;8(3):162.
20. Pires DP, Dötsch A, Anderson EM, et al. Lysis-deficient phages as novel therapeutic agents for controlling bacterial infection. PLoS Pathog. 2016;12(8):e1005757.
21. Torres-Barceló C, Hochberg ME. Evolutionary rationale for phages as complements of antibiotics. Trends Microbiol. 2016;24(4):249-256.
22. Migone TS, Subramanian GM, Zhong J, et al. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med. 2009;361(14):1358-1365.
23. Ng WL, Bassler BL. Functional potential of an interbacterial signaling molecule. Proc Natl Acad Sci U S A. 2019;116(25):12358-12362.
24. Outterson K, Rex JH. Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercialization. Transl Res. 2019;204:27-35.
25. Schmidt CS, Al-Lahham S, Licht N, et al. Impact of bacterial toxins on the onset of blood—brain barrier damage and brain edema formation during pneumococcal meningitis. Acta Neuropathol Commun. 2013;1(1):1-7.
26. Tornheim JA, Brusaferro S, Santos R, Harbarth S, Centre ETM. CARB-X: re-energizing the antibacterial pipeline. Ann N Y Acad Sci. 2019;1435(1):43.
27. Yang Z, Ramsey J, Hamza T, et al. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab. Infect Immun. 2017;85(4).